04.11.2020 M1 Kliniken AG  DE000A0STSQ8

DGAP-News: M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.


 

DGAP-News: M1 Kliniken AG / Key word(s): 9 Month figures/Expansion
M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.

04.11.2020 / 08:00
The issuer is solely responsible for the content of this announcement.



M1 Kliniken AG: Number of treatments increase by almost 20% in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.

Berlin, 4.11.2020 - In contrast to the worsening pandemic situation, M1 Kliniken AG continues to record strong demand. The number of injection treatments and surgical treatments performed in the German market in the 3rd quarter of 2020 rose by almost 20% year-on-year to over 65,000. The international locations are also expanding their market position and were able to significantly increase the number of treatments. In the 3rd quarter of 2020, a further practice was opened in Austria (Graz).

M1 Kliniken AG expects the positive development to continue in the 4th quarter 2020. To date, the company is not affected by the current lock-down arrangements and treatments will continue on the basis of a comprehensive hygiene concept. The Australian centers resumed operations at the end of October after a lock-down of more than three months. The high expectations for the restart were more than exceeded. In addition, the first practice in Eastern Europe (Zagreb/Croatia) was opened at the end of October 2020.

For the further expansion of the practice network, M1 Kliniken AG is closely monitoring the local pandemic developments. For the time being, no further international projects will be started and a sustained decline in the number of corona cases will be awaited. In the German market, four new locations are currently being developed in cities without M1 presence. M1 is also recruiting new doctors to further expand treatment capacities.

In addition, M1 has been involved in COVID19 testing since mid-year. Between July and October 2020, more than 25,000 test samples have been taken for corporate customers. A first COVID test centre in Berlin for "walk-in testing" as a prototype for further locations in Germany was opened in early November 2020.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, beauty medical treatments are currently offered at more than 35 locations. The 'M1 Schlossklinik' for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its international expansion and is currently active in Austria, the Netherlands and Australia. The Group is now also growing in other European countries and markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands.




Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: [email protected]


04.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: [email protected]
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate Exchange
EQS News ID: 1145081

 
End of News DGAP News Service

1145081  04.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1145081&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 47,19 65,21 77,27 159,59 314,61 285,29 302,00
EBITDA1,2 6,18 7,17 11,33 8,89 17,82 15,41 19,85
EBITDA-Marge3 13,10 11,00 14,66 5,57 5,66 5,40
EBIT1,4 5,71 6,46 7,93 4,41 12,13 9,35 14,40
EBIT-Marge5 12,10 9,91 10,26 2,76 3,86 3,28 4,77
Jahresüberschuss1 5,78 6,61 9,73 7,43 10,88 7,07 9,50
Netto-Marge6 12,25 10,14 12,59 4,66 3,46 2,48 3,15
Cashflow1,7 2,09 2,86 -5,37 9,54 15,68 20,77 0,00
Ergebnis je Aktie8 0,38 0,39 0,56 0,37 0,45 0,22 0,39
Dividende8 0,30 0,30 0,00 0,00 0,00 0,00 0,30
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: wetreu NTRG

INVESTOR-INFORMATIONEN
©boersengefluester.de
M1 Kliniken
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0STSQ 13,800 Kaufen 271,08
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
20,00 28,19 0,69 36,41
KBV KCV KUV EV/EBITDA
2,77 13,05 0,95 16,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.07.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
06.06.2024 03.09.2024 16.11.2023 23.05.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
10,21% 38,07% 23,21% 96,58%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu M1 Kliniken AG  ISIN: DE000A0STSQ8 können Sie bei EQS abrufen


Gesundheit , A0STSQ , M12 , XETR:M12